Cancer Tissue Diagnostics Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2030

Description

Persistence Market Research has recently conducted a thorough analysis of the Cancer Tissue Diagnostics Market, resulting in a comprehensive report detailing its global landscape. This in-depth publication provides valuable insights into the market's dynamics, trends, opportunities, and challenges, offering a comprehensive overview of its structure. Backed by exclusive data and statistics, the research predicts the anticipated growth trajectory of the Cancer Tissue Diagnostics Market spanning from 2023 to 2030.

The worldwide market for cancer tissue diagnostics is projected to grow at a compound annual growth rate (CAGR) of 6.9%, reaching a value of US$11.1 billion by the conclusion of 2030, up from US$6.9 billion in 2023.

Key Insights:

Cancer Tissue Diagnostics Market Size (2023E): US$6.9 Bn
Projected Market Value (2030F): US$11.1 Bn
Global Market Growth Rate (CAGR 2023 to 2030): 6.9%
Historical Market Growth Rate (CAGR 2018 to 2022): 5.7%

Cancer Tissue Diagnostics Market - Report Scope

Tissue diagnostics emerges as a notably dependable approach for cancer diagnosis and devising treatment strategies, encapsulating the biological intricacies of cancerous cells. The rising demand and prospective expansion in the cancer tissue diagnostics sector are driven by the increasing prevalence of cancer.

Several factors fuel this expansion, including the escalating incidence of various cancer types, a growing emphasis on preventive healthcare, the wider adoption of digital pathology, intensified cancer awareness campaigns, advancements in more efficient diagnostic and monitoring technologies, and an overall improvement in diagnostic precision. Together, these factors paint a promising picture for the global cancer tissue diagnostics landscape.

Market Growth Drivers

The growing burden of cancer, coupled with an aging population, underscores the importance of tissue-based diagnostics in oncology. For instance, in the UK, where cancer incidence is projected to increase from 3.5 million in 2025 to 4 million by 2030, the demand for tissue diagnostics is expected to rise. Factors such as a growing and aging population, increased cancer awareness, and improvements in cancer diagnosis infrastructure have contributed to a 19% surge in cancer incidence over the last decade.

Similarly, in France, where over 433 thousand new cancer cases were predicted in 2023, with prostate, lung, colorectal cancers being predominant among men, and breast, colorectal, and lung cancers among women, the demand for tissue diagnostics instruments and reagents is also expected to increase.

Market Restraints

Histology laboratories are critical for accurate and timely sickness diagnosis, particularly in understanding disease causes and treatment effectiveness, with 80% of cancer diagnostics relying on histology. However, these facilities face significant challenges due to understaffing and high retirement rates among histologists. For instance, in the UK, only 3% of diagnostic labs have sufficient staff to handle diagnostic tasks, while Germany has the lowest pathologist-to-physician ratio in Europe, the US, and Canada, potentially limiting the growth of the cancer tissue diagnostics industry.

In developing countries, financial constraints often prevent hospitals from investing in diagnostic imaging equipment. However, the increasing demand for diagnostic imaging has led many hospitals to opt for refurbished systems, which come at a lower cost, typically ranging from 40% to 60% of the original equipment cost. Market leaders such as Siemens, GE Healthcare, and Philips are actively promoting the use of refurbished devices through various programs, making diagnostic imaging more accessible in regions with limited financial resources.

Opportunities

The increased understanding of particular cancer biomarkers represents a substantial commercial opportunity for improving cancer patient treatment, supported by advancements in detection technology and equipment. Progress in biotechnology has facilitated the identification of potential cancer biomarkers, some of which have already entered commercialization. As a result, the introduction of novel diagnostic biomarkers is creating lucrative opportunities for the growth of the cancer diagnostics market.

Key Questions Answered in Report::

What is the current state of the cancer diagnostics market?
What are the main factors driving the growth of the cancer diagnostics market?
What are the key challenges facing the cancer diagnostics market?
What are the emerging trends and opportunities in the cancer diagnostics market?
Which regions or countries are witnessing significant growth in the cancer diagnostics market?
What are the most commonly used diagnostic techniques and technologies in cancer diagnosis?

Competitive Intelligence and Business Strategy

Leading organizations such as Abbott Laboratories, F. Hoffmann-La Roche Ltd., and Thermo Fisher Scientific Inc. are spearheading innovation in the cancer tissue diagnostics sector, leveraging their technological expertise and extensive healthcare industry experience. Companies like Abbott Laboratories and F. Hoffmann-La Roche are particularly focused on advancing diagnostic tests to provide critical information, with FISH tests playing a pivotal role in diagnosing solid neoplasms and hematologic biomarkers.

Moreover, these companies are actively involved in personalized medicine initiatives, recognizing the increasing demand for their products in digital pathology. This is expected to drive strategic partnerships within the global cancer tissue diagnostics industry, fostering collaborations between technology providers and digital pathology platforms.

In the competitive landscape, these businesses differentiate themselves by offering unique features such as precise tissue analysis, innovative biomarker identification, and comprehensive pathology solutions.

Key Companies Profiled

Abbott Laboratories
F. Hoffmann-La Roche Ltd.
Thermo Fisher Scientific Inc.
Ventana Medical Systems, Inc.
Bio Rad Laboratories Inc.
Enzo Life Sciences, Inc.
Abcam plc.
BioGenex
Cell Signalling Technology, Inc.
Agilent Technologies, Inc.
PerkinElmer Inc.
Bio SB
Cancer Genetics Inc.
Danaher Corporation
ROSETTA GENOMICS
Nanoprobes, Inc.
Creative-Biolabs
Enzo Life Sciences, Inc.
Sigma-Aldrich Co., LLC

Cancer Tissue Diagnostics Market Segmentation

By Test Type:

Breast Cancer
Stomach (Gastric) Cancer
Colorectal Cancer
Prostate Cancer
Others

By In Situ Hybridization (ISH) Test:

Breast Cancer
Non-Small Cell Lung Cancer (NSCLC)
Bladder Cancer
Others

By Region:

North America
Europe
East Asia
South Asia & Oceania
Latin America
Middle East & Africa

Product Code: PMRREP33842

1. Executive Summary

1.1. Global Cancer Tissue Diagnostics Market Snapshot, 2023 and 2030
1.2. Market Opportunity Assessment, 2023 - 2030, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations

2. Market Overview

2.1. Market Scope and Definition
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Challenges
- 2.2.5. Key Trends
2.3. Test Type Lifecycle Analysis
2.4. Cancer Tissue Diagnostics Market: Value Chain
- 2.4.1. List of Raw Material Supplier
- 2.4.2. List of Manufacturers
- 2.4.3. List of Distributors
- 2.4.4. List of Applications
- 2.4.5. Profitability Analysis
2.5. Porter Five Force's Analysis
2.6. Geopolitical Tensions: Market Impact
2.7. Macro-Economic Factors
- 2.7.1. Global Sectorial Outlook
- 2.7.2. Global GDP Growth Outlook
- 2.7.3. Global Parent Market Overview
2.8. Forecast Factors - Relevance and Impact
2.9. Regulatory and Technology Landscape

3. Global Cancer Tissue Diagnostics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

3.1. Key Highlights
- 3.1.1. Market Volume (Units) Projections
- 3.1.2. Market Size and Y-o-Y Growth
- 3.1.3. Absolute $ Opportunity
3.2. Market Size (US$ Mn) Analysis and Forecast
- 3.2.1. Historical Market Size Analysis, 2013-2016
- 3.2.2. Current Market Size Forecast, 2018-2026
3.3. Global Cancer Tissue Diagnostics Market Outlook: Test Type
- 3.3.1. Introduction / Key Findings
- 3.3.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Test Type, 2018 - 2022
- 3.3.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Test Type, 2023 - 2030
  - 3.3.3.1. Breast Cancer
  - 3.3.3.2. Stomach (Gastric) Cancer
  - 3.3.3.3. Colorectal Cancer
  - 3.3.3.4. Prostate Cancer
  - 3.3.3.5. Others
3.4. Market Attractiveness Analysis: Test Type
3.5. Global Cancer Tissue Diagnostics Market Outlook: In Situ Hybridization (ISH) Test
- 3.5.1. Introduction / Key Findings
- 3.5.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By In Situ Hybridization (ISH) Test, 2018 - 2022
- 3.5.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By In Situ Hybridization (ISH) Test, 2023 - 2030
  - 3.5.3.1. Breast Cancer
  - 3.5.3.2. Non-Small Cell Lung Cancer (NSCLC)
  - 3.5.3.3. Bladder Cancer
  - 3.5.3.4. Others
3.6. Market Attractiveness Analysis: In Situ Hybridization (ISH) Test

4. Global Cancer Tissue Diagnostics Market Outlook: Region

4.1. Key Highlights
4.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Region, 2018 - 2022
4.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Region, 2023 - 2030
- 4.3.1. North America
- 4.3.2. Europe
- 4.3.3. East Asia
- 4.3.4. South Asia and Oceania
- 4.3.5. Latin America
- 4.3.6. Middle East & Africa (MEA)
4.4. Market Attractiveness Analysis: Region

5. North America Cancer Tissue Diagnostics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

5.1. Key Highlights
5.2. Pricing Analysis
5.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 5.3.1. By Country
- 5.3.2. By Test Type
- 5.3.3. By In Situ Hybridization (ISH) Test
5.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 5.4.1. U.S.
- 5.4.2. Canada
5.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Test Type, 2023 - 2030
- 5.5.1. Breast Cancer
- 5.5.2. Stomach (Gastric) Cancer
- 5.5.3. Colorectal Cancer
- 5.5.4. Prostate Cancer
- 5.5.5. Others
5.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By In Situ Hybridization (ISH) Test, 2023 - 2030
- 5.6.1. Breast Cancer
- 5.6.2. Non-Small Cell Lung Cancer (NSCLC)
- 5.6.3. Bladder Cancer
- 5.6.4. Others
5.7. Market Attractiveness Analysis

6. Europe Cancer Tissue Diagnostics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

6.1. Key Highlights
6.2. Pricing Analysis
6.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 6.3.1. By Country
- 6.3.2. By Test Type
- 6.3.3. By In Situ Hybridization (ISH) Test
6.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 6.4.1. Germany
- 6.4.2. France
- 6.4.3. U.K.
- 6.4.4. Italy
- 6.4.5. Spain
- 6.4.6. Russia
- 6.4.7. Turkiye
- 6.4.8. Rest of Europe
6.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Test Type, 2023 - 2030
- 6.5.1. Breast Cancer
- 6.5.2. Stomach (Gastric) Cancer
- 6.5.3. Colorectal Cancer
- 6.5.4. Prostate Cancer
- 6.5.5. Others
6.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By In Situ Hybridization (ISH) Test, 2023 - 2030
- 6.6.1. Breast Cancer
- 6.6.2. Non-Small Cell Lung Cancer (NSCLC)
- 6.6.3. Bladder Cancer
- 6.6.4. Others
6.7. Market Attractiveness Analysis

7. East Asia Cancer Tissue Diagnostics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

7.1. Key Highlights
7.2. Pricing Analysis
7.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 7.3.1. By Country
- 7.3.2. By Test Type
- 7.3.3. By In Situ Hybridization (ISH) Test
7.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 7.4.1. China
- 7.4.2. Japan
- 7.4.3. South Korea
7.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Test Type, 2023 - 2030
- 7.5.1. Breast Cancer
- 7.5.2. Stomach (Gastric) Cancer
- 7.5.3. Colorectal Cancer
- 7.5.4. Prostate Cancer
- 7.5.5. Others
7.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By In Situ Hybridization (ISH) Test, 2023 - 2030
- 7.6.1. Breast Cancer
- 7.6.2. Non-Small Cell Lung Cancer (NSCLC)
- 7.6.3. Bladder Cancer
- 7.6.4. Others
7.7. Market Attractiveness Analysis

8. South Asia & Oceania Cancer Tissue Diagnostics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

8.1. Key Highlights
8.2. Pricing Analysis
8.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 8.3.1. By Country
- 8.3.2. By Test Type
- 8.3.3. By In Situ Hybridization (ISH) Test
8.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 8.4.1. India
- 8.4.2. Southeast Asia
- 8.4.3. ANZ
- 8.4.4. Rest of South Asia & Oceania
8.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Test Type, 2023 - 2030
- 8.5.1. Breast Cancer
- 8.5.2. Stomach (Gastric) Cancer
- 8.5.3. Colorectal Cancer
- 8.5.4. Prostate Cancer
- 8.5.5. Others
8.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By In Situ Hybridization (ISH) Test, 2023 - 2030
- 8.6.1. Breast Cancer
- 8.6.2. Non-Small Cell Lung Cancer (NSCLC)
- 8.6.3. Bladder Cancer
- 8.6.4. Others
8.7. Market Attractiveness Analysis

9. Latin America Cancer Tissue Diagnostics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

9.1. Key Highlights
9.2. Pricing Analysis
9.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 9.3.1. By Country
- 9.3.2. By Test Type
- 9.3.3. By In Situ Hybridization (ISH) Test
9.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 9.4.1. Brazil
- 9.4.2. Mexico
- 9.4.3. Rest of Latin America
9.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Test Type, 2023 - 2030
- 9.5.1. Breast Cancer
- 9.5.2. Stomach (Gastric) Cancer
- 9.5.3. Colorectal Cancer
- 9.5.4. Prostate Cancer
- 9.5.5. Others
9.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By In Situ Hybridization (ISH) Test, 2023 - 2030
- 9.6.1. Breast Cancer
- 9.6.2. Non-Small Cell Lung Cancer (NSCLC)
- 9.6.3. Bladder Cancer
- 9.6.4. Others
9.7. Market Attractiveness Analysis

10. Middle East & Africa Cancer Tissue Diagnostics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

10.1. Key Highlights
10.2. Pricing Analysis
10.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 10.3.1. By Country
- 10.3.2. By Test Type
- 10.3.3. By In Situ Hybridization (ISH) Test
10.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 10.4.1. GCC
- 10.4.2. Egypt
- 10.4.3. South Africa
- 10.4.4. Northern Africa
- 10.4.5. Rest of Middle East & Africa
10.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Test Type, 2023 - 2030
- 10.5.1. Breast Cancer
- 10.5.2. Stomach (Gastric) Cancer
- 10.5.3. Colorectal Cancer
- 10.5.4. Prostate Cancer
- 10.5.5. Others
10.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By In Situ Hybridization (ISH) Test, 2023 - 2030
- 10.6.1. Breast Cancer
- 10.6.2. Non-Small Cell Lung Cancer (NSCLC)
- 10.6.3. Bladder Cancer
- 10.6.4. Others
10.7. Market Attractiveness Analysis

11. Competition Landscape

11.1. Market Share Analysis, 2022
11.2. Market Structure
- 11.2.1. Competition Intensity Mapping By Market
- 11.2.2. Competition Dashboard
- 11.2.3. Apparent Product Capacity
11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 11.3.1. Abbott Laboratories
  - 11.3.1.1. Overview
  - 11.3.1.2. Segments and Product
  - 11.3.1.3. Key Financials
  - 11.3.1.4. Market Developments
  - 11.3.1.5. Market Strategy
- 11.3.2. F. Hoffmann-La Roche Ltd.
  - 11.3.2.1. Overview
  - 11.3.2.2. Segments and Product
  - 11.3.2.3. Key Financials
  - 11.3.2.4. Market Developments
  - 11.3.2.5. Market Strategy
- 11.3.3. Thermo Fisher Scientific Inc.
  - 11.3.3.1. Overview
  - 11.3.3.2. Segments and Product
  - 11.3.3.3. Key Financials
  - 11.3.3.4. Market Developments
  - 11.3.3.5. Market Strategy
- 11.3.4. Ventana Medical Systems, Inc.
  - 11.3.4.1. Overview
  - 11.3.4.2. Segments and Product
  - 11.3.4.3. Key Financials
  - 11.3.4.4. Market Developments
  - 11.3.4.5. Market Strategy
- 11.3.5. Bio Rad Laboratories Inc.
  - 11.3.5.1. Overview
  - 11.3.5.2. Segments and Product
  - 11.3.5.3. Key Financials
  - 11.3.5.4. Market Developments
  - 11.3.5.5. Market Strategy
- 11.3.6. Enzo Life Sciences, Inc.
  - 11.3.6.1. Overview
  - 11.3.6.2. Segments and Product
  - 11.3.6.3. Key Financials
  - 11.3.6.4. Market Developments
  - 11.3.6.5. Market Strategy
- 11.3.7. Abcam plc.
  - 11.3.7.1. Overview
  - 11.3.7.2. Segments and Product
  - 11.3.7.3. Key Financials
  - 11.3.7.4. Market Developments
  - 11.3.7.5. Market Strategy
- 11.3.8. BioGenex
  - 11.3.8.1. Overview
  - 11.3.8.2. Segments and Product
  - 11.3.8.3. Key Financials
  - 11.3.8.4. Market Developments
  - 11.3.8.5. Market Strategy
- 11.3.9. Cell Signalling Technology, Inc.
  - 11.3.9.1. Overview
  - 11.3.9.2. Segments and Product
  - 11.3.9.3. Key Financials
  - 11.3.9.4. Market Developments
  - 11.3.9.5. Market Strategy
- 11.3.10. Agilent Technologies, Inc.
  - 11.3.10.1. Overview
  - 11.3.10.2. Segments and Product
  - 11.3.10.3. Key Financials
  - 11.3.10.4. Market Developments
  - 11.3.10.5. Market Strategy
- 11.3.11. PerkinElmer Inc.
  - 11.3.11.1. Overview
  - 11.3.11.2. Segments and Product
  - 11.3.11.3. Key Financials
  - 11.3.11.4. Market Developments
  - 11.3.11.5. Market Strategy
- 11.3.12. Bio SB
  - 11.3.12.1. Overview
  - 11.3.12.2. Segments and Product
  - 11.3.12.3. Key Financials
  - 11.3.12.4. Market Developments
  - 11.3.12.5. Market Strategy
- 11.3.13. Cancer Genetics Inc.
  - 11.3.13.1. Overview
  - 11.3.13.2. Segments and Product
  - 11.3.13.3. Key Financials
  - 11.3.13.4. Market Developments
  - 11.3.13.5. Market Strategy
- 11.3.14. Danaher Corporation
  - 11.3.14.1. Overview
  - 11.3.14.2. Segments and Product
  - 11.3.14.3. Key Financials
  - 11.3.14.4. Market Developments
  - 11.3.14.5. Market Strategy
- 11.3.15. ROSETTA GENOMICS
  - 11.3.15.1. Overview
  - 11.3.15.2. Segments and Product
  - 11.3.15.3. Key Financials
  - 11.3.15.4. Market Developments
  - 11.3.15.5. Market Strategy
- 11.3.16. Nanoprobes, Inc.
  - 11.3.16.1. Overview
  - 11.3.16.2. Segments and Product
  - 11.3.16.3. Key Financials
  - 11.3.16.4. Market Developments
  - 11.3.16.5. Market Strategy
- 11.3.17. Creative-Biolabs
  - 11.3.17.1. Overview
  - 11.3.17.2. Segments and Product
  - 11.3.17.3. Key Financials
  - 11.3.17.4. Market Developments
  - 11.3.17.5. Market Strategy
- 11.3.18. Enzo Life Sciences, Inc.
  - 11.3.18.1. Overview
  - 11.3.18.2. Segments and Product
  - 11.3.18.3. Key Financials
  - 11.3.18.4. Market Developments
  - 11.3.18.5. Market Strategy
- 11.3.19. Sigma-Aldrich Co., LLC
  - 11.3.19.1. Overview
  - 11.3.19.2. Segments and Product
  - 11.3.19.3. Key Financials
  - 11.3.19.4. Market Developments
  - 11.3.19.5. Market Strategy

12. Appendix

12.1. Research Methodology
12.2. Research Assumptions
12.3. Acronyms and Abbreviations